Wire · opportunities
FDA Approves First-in-Class Drug for Polycythemia Vera
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
The FDA approved rusfertide (Mimrylo) as the first drug targeting the hepcidin pathway to control hematocrit in adults with polycythemia vera, based on positive results from a phase 3 clinical trial.
This Wire brief sits within Fusion42's coverage of Biotech, and 12 sources have reported it between 28 Aug 2026 and 1 Sep 2026.
◆ ◆ The Wire takeaway
You can now develop therapies targeting the hepcidin pathway for blood disorders with clear regulatory precedent in the US. This opens the door to a new treatment class, so shift R&D focus to explore hepcidin modulation before competitors do.
◆ Coverage
12 sources · first reported 28 Aug 2026 · latest 1 Sep 2026
◆ Related on Wire
◆ Topics